DR REDDY'S FORMULATIONS LIMITED
Location
Telangana
Founded
2021-03-11
Website
Risk Signals
2 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Chemicals and Chemical Preparations, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about DR REDDY'S FORMULATIONS LIMITED
Live alerts from global media, monitored by Business Radar
2025-02-06 (stocktitan.net)
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Henlius partners with Dr. Reddy's, receiving $33M upfront plus $131.6M in potential milestones for HLX15 daratumumab biosimilar rights across US and European markets.
Read more
2023-10-25 (inc42.com)
Dr. Reddy’s Marks Its Ecommerce Foray With The Launch Of Celevida Wellness
The new ecommerce marketplace lists both Celevida products and other third-party brands on its website, and will be focussed on Type 2 diabetic and pre-diabetic individuals.
Read more